암 바이오마커 시장: 2026년까지의 세계 예측

출판: MarketsandMarkets(마켓츠앤드마켓츠)출판년월:2022년03월

유형(단백질, 유전), 암(폐, 유방, 백혈병, 흑색종, 결장 직장), 프로파일링 기술(오믹스, 이미징, 면역분석, 바이오인포매틱스), 용도(진단, R&D, 예후), 지역별 – 2026년 까지의 세계 예측

Cancer Biomarkers Market by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region – Global Forecast to 2026

폐이지수 278
도표수 279
가격
Single User License USD7,150
Multi User License(5명) USD8,500
Corporate(site) License USD9,650
Enterprise License USD11,000
구성 영문조사보고서

리포트목차보기    견적・문의・의뢰로 이동    구입안내

Sample Request

세계 암 바이오마커 시장은 2021년에 124억 달러, 2026년까지는 282억 달러에 이르며 예측 기간의 CAGR 17.7%로 성장할 것으로 예측되고 있습니다。

MarketsandMarkets「암 바이오마커 시장: 유형(단백질, 유전), 암(폐, 유방, 백혈병, 흑색종, 결장 직장), 프로파일링 기술(오믹스, 이미징, 면역분석, 바이오인포매틱스), 용도 (진단, R&D, 예후), 지역별 – 2026년까지의 세계 예측 – Cancer Biomarkers Market by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region – Global Forecast to 2026」은 세계 암의 바이오마커 시장을 조사하여 주요 세그먼트별로 실시한 분석 및 예측 결과를 제공하고 있습니다。

주요 게시물

    • 시장 개요
    • 바이오마커 유형별 암 바이오마커 시장
      • 단백질 바이오마커
      • 제네틱 바이오마커
      • 기타 암 바이오마커
    • 암 유형별 암 바이오마커 시장
      • 유방암
      • 폐암
      • 대장암(CRC)
      • 전립선암
      • 악성 흑색종(흑색종)
      • 백혈병
      • 갑상선암
      • 방광암
      • 비호지킨 림프종
      • 신장암
      • 기타 암
    • 프로필링 기술별 암 바이오마커 시장
      • OMICS 기술
      • 게노믹스
      • 이미지 기술
      • 면역측정법(면역검정)
      • 생물정보학(바이오인포매틱스)
      • 세포 유전학
    • 용도별 암 바이오마커 시장
      • 진단
      • 연구개발
      • 예후
      • 위험 평가
      • 기타 사용
    • 지역별 암 바이오마커 시장
      • 북미
      • 유럽
      • 아시아 태평양 지역
      • 라틴 아메리카
      • 중동 및 아프리카
    • 경쟁 환경
    • 기업 정보
    • 부록

The global cancer biomarkersmarket is projected to reach USD 28.2billion by 2026 from USD 12.4billion in 2021, at a CAGR of 17.7% during the forecast period. Market growth is driven by factors such as therising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide. On the other hand, challenges associated with cancer biomarker validationand shortage of skilled professionalsare the major factors hampering the growth of this market.
“The protein biomarkers segment accounted for the highest growth rate in thecancer biomarkersmarket, by biomarker type, during the forecast period”
Thecancer biomarkersmarket is segmented into protein biomarkers, genetic biomarkers and other cancer biomarkers based on biomarkers type. In 2020, the protein biomarkerssegment accounted for the highest growth rate in the cancer biomarkersmarket.Increasing incidence of cancer worldwide and increasing R&D on cancer biomarkersare major factor contributing to the growth of this segment.
“The breast cancersegment accounted for the highest growth rate in the cancer biomarkers market, by cancer type, during the forecast period”
The cancer biomarkers market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, non-hodgkin’s lymphoma, kidney cancer and other cancer typesbased on cancer type. In 2020, the breast cancer segment accounted for the highest growth rate in the cancer biomarkers market. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwideare major factors contributing to the growth of this segment.
“Bioinformaticssegment accounted for the highest CAGR”
Based onprofiling technologies, cancer biomarkers market has been segmented into omics technologies, imaging technologies, immunoassay, bioinformatics and cytogenetics. In 2020, the bioinformaticssegment accounted for the highest CAGR. This can be attributed to theincreasing use of cancer biomarkers in drug discovery & development.
“Diagnostics segment accounted for the highest share”
Based on application, the cancer biomarkers market has been segmented into diagnostics, research & development, prognostics, risk assessment and other applications. In 2020, the research & development segment accounted for the highest CAGR. This can be attributed to the increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers.

“Asia Pacific: The fastest-growing regionin cancer biomarkersmarket”
The global cancer biomarkersmarket is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Rising technological advancements In the development of cancer biomarkers and increasing incidence of cancer worldwide are driving the growth of the cancer biomarkersmarket in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Thermo Fisher Scientific, Inc. (US)
• QIAGEN N.V. (Netherlands)
• Illumina, Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• Abbott Laboratories (US)
• bioMérieux SA (US)
• Becton, Dickinson and Company (US)
• Merck Millipore (US)
• Agilent Technologies (US)
• Myriad Genetics, Inc. (US)
• Sysmex Corporation (Japan)
• Hologic, Inc. (US)
• Quest Diagnostics (US)
• Centogene N.V. (Germany)
• PerkinElmer, Inc. (US)
• Siemens Healthineers (Germany)
• Exact Sciences (US)
• R&D Systems, Inc. (US)
• BioVision, Inc. (US)
• Olink (Sweden)
• Asuragen, Inc. (US)
• Meso Scale Diagnostics, LLC (US)
• Invivoscribe, Inc. (US)
• Seegene Technologies, Inc. (South Korea)


Research Coverage:
This report provides a detailed picture of the global cancer biomarkersmarket. It aims at estimating the size and future growth potential of the market across different segments, such as biomarkers type, cancer type, profiling technologies, application and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cancer biomarkersmarket and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 35)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 41)
    2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 CANCER BIOMARKERS MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET
2.9 GROWTH RATE ASSUMPTIONS
2.10 COVID-19 HEALTH ASSESSMENT
2.11 COVID-19 ECONOMIC ASSESSMENT
2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF GLOBAL ECONOMY
2.13 ASSESSMENT OF IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET

3 EXECUTIVE SUMMARY (Page No. – 58)
FIGURE 11 CANCER BIOMARKERS MARKET, BY BIOMARKERS TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 14 CANCER BIOMARKERS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. – 62)
4.1 CANCER BIOMARKERS MARKET OVERVIEW
FIGURE 16 RISING TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF CANCER BIOMARKERS TO DRIVE MARKET GROWTH
4.2 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2021 VS. 2026
FIGURE 17 THE PROTEIN BIOMARKERS SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2021 VS. 2026
FIGURE 18 LUNG CANCER SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.4 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2021 VS. 2026
FIGURE 19 THE OMICS TECHNOLOGIES SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2021 VS. 2026
FIGURE 20 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.6 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 66)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising technological advancements in the development of cancer biomarkers
5.2.1.2 Increasing incidence of cancer worldwide
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015─2O35
5.2.1.3 Increasing use of cancer biomarkers in drug discovery & development
5.2.1.4 Increasing R&D on cancer biomarkers
5.2.2 RESTRAINTS
5.2.2.1 Technical issues related to sample collection and storage
5.2.2.2 High capital investments and extensive timelines for the development of cancer biomarkers
TABLE 3 TIMEFRAME FOR THE DEVELOPMENT OF BIOMARKERS
5.2.2.3 Unfavorable regulatory and reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Increased recognition of personalized medicine
FIGURE 23 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
5.2.3.2 Growing application areas of companion diagnostics
5.2.3.3 Emerging economies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with cancer biomarker validation
5.2.4.2 Shortage of skilled professionals
5.3 IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
5.4.1 CANCER BIOMARKERS MARKET
FIGURE 24 PESSIMISTIC SCENARIO
FIGURE 25 OPTIMISTIC SCENARIO
FIGURE 26 REALISTIC SCENARIO
5.5 PRICING ANALYSIS
TABLE 4 PRICE OF CANCER BIOMARKERS BY PRODUCT & SERVICE (2021)
5.6 PATENT ANALYSIS
5.6.1 PATENT ANALYSIS OF THE CANCER BIOMARKERS MARKET
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
TABLE 5 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 6 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION)
5.8 VALUE CHAIN ANALYSIS
FIGURE 27 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
5.10.1 ROLE IN ECOSYSTEM
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES:
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 BARGAINING POWER OF SUPPLIERS
5.11.5 DEGREE OF COMPETITION
5.12 REGULATORY ANALYSIS
5.12.1 INTRODUCTION
5.12.2 CANCER BIOMARKERS QUALIFICATION IN THE US
5.12.3 CANCER BIOMARKERS QUALIFICATION IN THE EU
5.12.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US
5.12.5 METHOD: EMA APPROVALS
5.12.6 METHOD: FDA APPROVALS
5.13 TECHNOLOGY ANALYSIS
5.14 PESTLE ANALYSIS
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
FIGURE 30 YC-YCC SHIFT FOR CANCER BIOMARKERS MARKET

6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE (Page No. – 93)
6.1 INTRODUCTION
TABLE 8 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 9 CANCER BIOMARKERS MARKET FOR BIOMARKERS TYPE, BY REGION, 2020–2026 (USD MILLION)
6.2 PROTEIN BIOMARKERS
6.2.1 INCREASED EFFORTS OF PHARMACEUTICAL COMPANIES TO DISCOVER PROTEIN BIOMARKERS FOR EARLY STAGES TO DRIVE MARKET GROWTH
TABLE 10 CANCER BIOMARKERS MARKET FOR PROTEIN BIOMARKERS, BY REGION, 2020–2026 (USD MILLION)
6.3 GENETIC BIOMARKERS
6.3.1 ADVANCEMENTS IN HIGH-THROUGHPUT TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 11 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS, BY TYPE, 2020–2026 (USD MILLION)
TABLE 12 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS, BY REGION, 2020–2026 (USD MILLION)
6.3.2 LUNG CANCER
6.3.3 BREAST CANCER
6.3.4 PROSTATE CANCER
6.3.5 LEUKEMIA
6.3.6 OTHER CANCERS
6.4 OTHER CANCER BIOMARKERS
TABLE 13 CANCER BIOMARKERS MARKET FOR OTHER CANCER BIOMARKERS, BY REGION, 2020–2026 (USD MILLION)

7 CANCER BIOMARKERS MARKET, BY CANCER TYPE (Page No. – 103)
7.1 INTRODUCTION
TABLE 14 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 15 CANCER BIOMARKERS MARKET FOR CANCER TYPE, BY REGION, 2020–2026 (USD MILLION)
7.2 BREAST CANCER
7.2.1 AVAILABILITY & UTILISATION OF ADVANCED TECHNOLOGIES BY MAJOR PLAYERS IN BREAST CANCER DETECTION TO DRIVE MARKET GROWTH
TABLE 16 BREAST CANCER INCIDENCE, BY REGION, 2020 VS 2040
TABLE 17 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2020–2026 (USD MILLION)
7.3 LUNG CANCER
7.3.1 INCREASING FOCUS ON LUNG CANCER BIOMARKERS DEVELOPMENT TO DRIVE MARKET GROWTH
TABLE 18 LUNG CANCER INCIDENCE, BY REGION, 2020 VS 2040
TABLE 19 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2020–2026 (USD MILLION)
7.4 COLORECTAL CANCER (CRC)
7.4.1 RISING DEMAND FOR BIOMARKERS IN THE EARLY DIAGNOSIS & PROGNOSIS OF CRC TO DRIVE THE MARKET GROWTH
TABLE 20 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS 2040
TABLE 21 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2026 (USD MILLION)
7.5 PROSTATE CANCER
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES ARE ENABLING THE DEVELOPMENT OF NEW BIOMARKERS FOR PROSTATE CANCER
TABLE 22 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2020–2026 (USD MILLION)
7.6 MELANOMA
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE THE MARKET GROWTH
TABLE 23 MELANOMA INCIDENCE, BY REGION, 2020 VS 2040
TABLE 24 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION, 2020–2026 (USD MILLION)
7.7 LEUKEMIA
7.7.1 RESEARCH STUDIES FOR THE DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS IN LEUKEMIA TO DRIVE MARKET GROWTH
TABLE 25 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION, 2020–2026 (USD MILLION)
7.8 THYROID CANCER
7.8.1 RESEARCH UNDERTAKEN FOR THE IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO DRIVE THE MARKET GROWTH
TABLE 26 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION, 2020–2026 (USD MILLION)
7.9 BLADDER CANCER
7.9.1 APPROVAL OF SEVERAL URINARY BIOMARKERS FOR THE DETECTION OF BLADDER CANCER TO SUPPORT THE SEGMENT GROWTH
TABLE 27 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION, 2020–2026 (USD MILLION)
7.10 NON-HODGKIN’S LYMPHOMA (NHL)
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE THE MARKET GROWTH
TABLE 28 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2020–2026 (USD MILLION)
7.11 KIDNEY CANCER
7.11.1 DEVELOPMENT OF SEVERAL NEW TARGETED THERAPIES FOR THE TREATMENT OF KIDNEY CANCER TO DRIVE THE MARKET GROWTH
TABLE 29 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION, 2020–2026 (USD MILLION)
7.12 OTHER CANCERS
TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2020–2026 (USD MILLION)

8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY (Page No. – 118)
8.1 INTRODUCTION
TABLE 31 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY TYPE, 2020–2026 (USD MILLION)
TABLE 32 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION)
8.2 OMICS TECHNOLOGY
8.2.1 INCREASING DEMAND FOR ADVANCED OMICS TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 33 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY TYPE, 2020–2026 (USD MILLION)
TABLE 34 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION)
8.2.2 PROTEOMICS
8.2.2.1 Increasing discovery rate of protein biomarkers and the rising need for rapid and cost-efficient diagnostic tests to drive segment growth
TABLE 35 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2020–2026 (USD MILLION)
8.2.3 GENOMICS
8.2.3.1 The rising potential of genomics technologies in the development of biomarkers for disease prediction
TABLE 36 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2020–2026 (USD MILLION)
TABLE 37 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2020–2026 (USD MILLION)
8.2.3.2 NEXT-GENERATION SEQUENCING (NGS)
8.2.3.2.1 Introducing advanced NGS platforms by leading players to increase productivity to drive the growth of this segment
TABLE 38 CANCER BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2020–2026 (USD MILLION)
8.2.3.3 POLYMERASE CHAIN REACTION (PCR)
8.2.3.3.1 Cost-effectiveness and the easy availability of PCR tests to propel the growth of this segment
TABLE 39 CANCER BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2026 (USD MILLION)
8.2.4 OTHER OMICS TECHNOLOGIES
TABLE 40 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2020–2026 (USD MILLION)
8.3 IMAGING TECHNOLOGIES
8.3.1 THE USE OF IMAGING BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT PROCESSES TO DRIVE THE GROWTH OF THIS MARKET
TABLE 41 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2020–2026 (USD MILLION)
TABLE 42 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2020–2026 (USD MILLION)
8.3.2 ULTRASOUND IMAGING
8.3.2.1 Use of ultrasound for biomarker research in the understanding of disease onset & progression to drive the growth of this segment
TABLE 43 CANCER BIOMARKERS MARKET FOR ULTRASOUND IMAGING, BY REGION, 2020–2026 (USD MILLION)
8.3.3 COMPUTED TOMOGRAPHY (CT)
8.3.3.1 The adoption of CT in cancer biomarker discovery is increasing rapidly
TABLE 44 CANCER BIOMARKERS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
8.3.4 MAGNETIC RESONANCE IMAGING (MRI)
8.3.4.1 MRI use in differentiating normal and diseased tissues to pinpoint cancerous cells precisely supports the growth of this segment
TABLE 45 CANCER BIOMARKERS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2020–2026 (USD MILLION)
8.3.5 POSITRON EMISSION TOMOGRAPHY (PET)
8.3.5.1 Development of lab-on-chip-based multiplex assays to support the market growth
TABLE 46 CANCER BIOMARKERS MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
8.3.6 MAMMOGRAPHY
8.3.6.1 Advanced technologies like 3D mammography to drive the growth of this segment
TABLE 47 CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
8.4 IMMUNOASSAYS
8.4.1 THE INCREASING PREVALENCE OF BREAST CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
TABLE 48 CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2026 (USD MILLION)
8.5 BIOINFORMATICS
8.5.1 RISING TECHNOLOGICAL ADVANCEMENTS AND THE GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET GROWTH
TABLE 49 CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION, 2020–2026 (USD MILLION)
8.6 CYTOGENETICS
8.6.1 CYTOGENETICS ARE GENETICS-BASED TESTS THAT ARE RELIABLE IN THE QUANTITATIVE & QUALITATIVE EVALUATION OF BIOMARKERS
TABLE 50 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY TYPE, 2020–2026 A(USD MILLION)
TABLE 51 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION, 2020–2026 (USD MILLION)
8.6.2 IN-SITU HYBRIDIZATION (ISH)
8.6.2.1 Use of ISH-based diagnostic tests help identify specific biomarkers in clinical trials
TABLE 52 CANCER BIOMARKERS MARKET FOR IN-SITU HYBRIDIZATION, BY REGION, 2020–2026 (USD MILLION)
8.6.3 OTHER CYTOGENETICS-BASED TESTS
TABLE 53 CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY REGION, 2020–2026 (USD MILLION)

9 CANCER BIOMARKERS MARKET, BY APPLICATION (Page No. – 140)
9.1 INTRODUCTION
TABLE 54 CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
TABLE 55 CANCER BIOMARKERS MARKET FOR APPLICATION, BY REGION, 2020–2026 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO DRIVE MARKET GROWTH
TABLE 56 CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2020–2026 (USD MILLION)
9.3 RESEARCH & DEVELOPMENT
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON BIOMARKERS USE IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET GROWTH
TABLE 57 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT, BY REGION, 2020–2026 (USD MILLION)
9.4 PROGNOSTICS
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO DRIVE MARKET GROWTH
TABLE 58 CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION, 2020–2026 (USD MILLION)
9.5 RISK ASSESSMENT
9.5.1 RISK ASSESSMENT BIOMARKERS TO INCREASE CANCER CLINICAL TRIALS FOR DRUG DEVELOPMENT
TABLE 59 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2020–2026 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 60 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2026 (USD MILLION)

10 CANCER BIOMARKERS MARKET, BY REGION (Page No. – 147)
10.1 INTRODUCTION
TABLE 61 CANCER BIOMARKERS MARKET, BY REGION, 2020–2026 (USD MILLION)
10.2 NORTH AMERICA
TABLE 62 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY CANCER TYPE
FIGURE 31 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 32 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 63 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.2.1.1 Increasing use of cancer biomarkers for cancer treatment drives the market growth
TABLE 72 KEY GROWTH STRATEGIES BY LEADING PLAYER FOR THE DEVELOPMENT OF CANCER BIOMARKERS
TABLE 73 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 74 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 75 US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 76 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 77 US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 78 US: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 79 US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 80 US: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 81 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing government initiatives for the discovery & development of cancer biomarkers to drive the market growth
TABLE 82 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 83 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 84 CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 85 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 86 CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 87 CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 88 CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 89 CANADA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 90 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3 EUROPE
FIGURE 33 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
TABLE 91 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 92 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 93 EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 94 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY , 2020–2026 (USD MILLION)
TABLE 95 EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 96 EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 97 EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 98 EUROPE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 99 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Favorable government health policies to drive the market growth for cancer biomarkers in Germany
TABLE 100 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 101 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 102 GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 103 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 104 GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 105 GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 106 GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 107 GERMANY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 108 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms have significantly boosted the adoption of biomarkers in the UK
TABLE 109 UK: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 110 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 111 UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 112 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY , 2020–2026 (USD MILLION)
TABLE 113 UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 114 UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 115 UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 116 UK: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 117 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government investments in genomics & proteomics research to drive the market growth in France
TABLE 118 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 119 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 120 FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 121 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 122 FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 123 FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 124 FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 125 FRANCE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 126 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increasing research activities on the discovery for novel cancer biomarkers using tissue diagnostic techniques to drive the market growth
TABLE 127 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 128 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 129 ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 130 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 131 ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 132 ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 133 ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 134 ITALY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 135 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Increasing focus on personalized medicine to drive the market growth for cancer biomarkers in Spain
TABLE 136 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 137 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 138 SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 139 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 140 SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 141 SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 142 SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 143 SPAIN: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 144 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 145 ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 146 ROE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 147 ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 148 ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 149 ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 150 ROE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 151 ROE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 152 ROE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
FIGURE 34 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 153 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 154 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 155 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 156 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 157 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 158 ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 159 ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 160 ASIA PACIFIC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 161 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
10.3.7 CHINA
10.3.7.1 Increasing burden of diseases and growing focus on novel drugs development to drive demand for cancer biomarkers
TABLE 162 CHINA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040
TABLE 163 CHINA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 164 CHINA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 165 CHINA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 166 CHINA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 167 CHINA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 168 CHINA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 169 CHINA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 170 CHINA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
10.3.8 JAPAN
10.3.8.1 Strategic collaborations with leading pharmaceutical companies to drive market growth
TABLE 171 JAPAN: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040
TABLE 172 JAPAN: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 173 JAPAN: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 174 JAPAN: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 175 JAPAN: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 176 JAPAN: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 177 JAPAN: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 178 JAPAN: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 179 JAPAN: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
10.3.9 INDIA
10.3.9.1 Increased demand for early cancer diagnosis to support market growth
TABLE 180 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 181 INDIA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 182 INDIA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 183 INDIA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 184 INDIA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 185 INDIA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 186 INDIA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 187 INDIA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 188 INDIA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
10.3.10 REST OF ASIA PACIFIC
TABLE 189 ROAPAC: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 190 ROAPAC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 191 ROAPAC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 192 ROAPAC: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 193 ROAPAC: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 194 ROAPAC: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 195 ROAPAC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 196 ROAPAC: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
10.4 LATIN AMERICA
10.4.1 GROWING CANCER RESEARCH AND MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 197 LATIN AMERICA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040
TABLE 198 LATIN AMERICA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 199 LATIN AMERICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 200 LATIN AMERICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 201 LATIN AMERICA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 202 LATIN AMERICA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 203 LATIN AMERICA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 204 LATIN AMERICA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 205 LATIN AMERICA: CYTOGENETICS MARKET BY APPLICATION, 2020–2026 (USD MILLION)
10.5 MIDDLE EAST & AFRICA
10.5.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
TABLE 206 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION)
TABLE 207 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION)
TABLE 209 MIDDLE EAST & AFRICA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 210 MIDDLE EAST & AFRICA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 211 MIDDLE EAST & AFRICA: IMAGING TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 212 MIDDLE EAST & AFRICA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION)
TABLE 213 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. – 223)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE CANCER BIOMARKERS MARKET
TABLE 214 STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 36 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET
11.4 MARKET SHARE ANALYSIS
TABLE 215 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 39 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2020
11.7 COMPETITIVE BENCHMARKING
FIGURE 40 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET
TABLE 216 COMPANY PRODUCT FOOTPRINT
TABLE 217 COMPANY REGIONAL FOOTPRINT
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 218 KEY PRODUCT LAUNCHES & APPROVALS
11.8.2 DEALS
TABLE 219 DEALS

12 COMPANY PROFILES (Page No. – 234)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 220 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
12.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 221 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
12.1.3 QIAGEN N.V.
TABLE 222 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2020)
12.1.4 ILLUMINA, INC.
TABLE 223 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT
12.1.5 BIO-RAD LABORATORIES, INC.
TABLE 224 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
12.1.6 ABBOTT LABORATORIES
TABLE 225 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
12.1.7 BIOMÉRIEUX SA
TABLE 226 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 47 BIOMÉRIEUX SA: COMPANY SNAPSHOT
12.1.8 BECTON DICKINSON AND COMPANY
TABLE 227 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
12.1.9 MERCK MILLIPORE
TABLE 228 MERCK MILLIPORE: BUSINESS OVERVIEW
FIGURE 49 MERCK MILLIPORE: COMPANY SNAPSHOT
12.1.10 AGILENT TECHNOLOGIES
TABLE 229 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 50 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
12.2 OTHER PLAYERS
12.2.1 MYRIAD GENETICS, INC.
12.2.2 SYSMEX CORPORATION
12.2.3 HOLOGIC, INC.
12.2.4 QUEST DIAGNOSTICS
12.2.5 CENTOGENE N.V.
12.2.6 PERKINELMER, INC.
12.2.7 SIEMENS HEALTHINEERS
12.2.8 EXACT SCIENCES
12.2.9 R&D SYSTEMS, INC.
12.2.10 BIOVISION INC.
12.2.11 OLINK
12.2.12 ASURAGEN, INC.
12.2.13 MESO SCALE DIAGNOSTICS, LLC
12.2.14 INVIVOSCRIBE, INC.
12.2.15 SEEGENE TECHNOLOGIES, INC.
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. – 280)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS


お問合せフォーム

    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com